Stereotaxic administrations of allogeneic human Vg9Vd2 T cells efficiently control the development of human glioblastoma brain tumors
ABSTRACT Glioblastoma multiforme (GBM) represents the most frequent and deadliest primary brain tumor. Aggressive treatment still fails to eliminate deep brain infiltrative and highly resistant tumor cells. Human Vg9Vd2 T cells, the major peripheral blood gd T cell subset, react against a wide array of tumor cells and represent attractive immune effector T cells for the design of antitumor therapies. This study aims at providing a preclinical rationale for immunotherapies in GBM based on stereotaxic administration of allogeneic human Vg9Vd2 T cells. The feasibility and the antitumor efficacy of stereotaxic Vg9Vd2 T cell injections have been investigated in orthotopic GBM mice model using selected heterogeneous and invasive primary human GBM cells. Allogeneic human Vg9Vd2 T cells survive and patrol for several days within the brain parenchyma following adoptive transfer and can successfully eliminate infiltrative GBM primary cells. These striking observations pave the way for optimized stereotaxic antitumor immunotherapies targeting human allogeneic Vg9Vd2 T cells in GBM patients.
Oncoimmunology